Previous literature reported that OPN binding to CD44 and integrin may increase inflammatory progression and joint destruction of articular cartilage in both OA and RA, and inhibiting this mechanism may be a hopeful strategy for OA therapy (16, 20, 43). This evidence concerns the gene SPP1 and rheumatoid arthritis.